Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Keating

Showing results (951-960 of 1,115) with videos related to

Pageof 112
Sort By:
Leukemia|August 8, 2022
A phase two study of high dose blinatumomab in Richter's syndromePhilip A Thompson, Xianli Jiang, Pinaki Banerjee, et al.
Endocrinology|February 3, 2021
Evidence for Glucagon Secretion and Function Within the Human GutEmily W Sun, Alyce M Martin, Dayan de Fontgalland, et al.
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2022
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia CellsUri Rozovski, Ivo Veletic, David M Harris, et al.
Blood|March 12, 2014
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemiaLorenzo Falchi, Michael J Keating, Edith M Marom, et al.
Diabetes|February 9, 2017
Local Sphingosine Kinase 1 Activity Improves Islet TransplantationDarling Rojas-Canales, Daniella Penko, Kay K Myo Min, et al.
British Journal of Haematology|September 10, 2016
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective studyPhilip A Thompson, Vincent Lévy, Constantine S Tam, et al.
Blood Advances|May 12, 2019
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLLPaolo Strati, Koichi Takahashi, Christine B Peterson, et al.
Brain : a Journal of Neurology|May 19, 2016
CSF1R mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroidsFlorian S Eichler, Jiankang Li, Yiran Guo, et al.
Plos One|December 31, 2013
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cellsStefania Fiorcari, Wells S Brown, Bradley W McIntyre, et al.
Pageof 112

Showing results (951-960 of 1,115) with videos related to

Sort By:
Pageof 112
Leukemia|August 8, 2022
A phase two study of high dose blinatumomab in Richter's syndromePhilip A Thompson, Xianli Jiang, Pinaki Banerjee, et al.
Endocrinology|February 3, 2021
Evidence for Glucagon Secretion and Function Within the Human GutEmily W Sun, Alyce M Martin, Dayan de Fontgalland, et al.
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2022
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia CellsUri Rozovski, Ivo Veletic, David M Harris, et al.
Blood|March 12, 2014
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemiaLorenzo Falchi, Michael J Keating, Edith M Marom, et al.
Diabetes|February 9, 2017
Local Sphingosine Kinase 1 Activity Improves Islet TransplantationDarling Rojas-Canales, Daniella Penko, Kay K Myo Min, et al.
British Journal of Haematology|September 10, 2016
Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective studyPhilip A Thompson, Vincent Lévy, Constantine S Tam, et al.
Blood Advances|May 12, 2019
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLLPaolo Strati, Koichi Takahashi, Christine B Peterson, et al.
Brain : a Journal of Neurology|May 19, 2016
CSF1R mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroidsFlorian S Eichler, Jiankang Li, Yiran Guo, et al.
Plos One|December 31, 2013
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cellsStefania Fiorcari, Wells S Brown, Bradley W McIntyre, et al.
Pageof 112